Company Overview
Snapshot
Founded in December 2015, Sade Group operates with 1–10 employees. The company has completed one funding round. A notable development occurred in May 2019 when Ori Yehudai, following the $7.1 billion sale of Frutarom, joined Sade Group as an active chairman and investor.
Business overview
Sade Group develops ASAYA, a platform designed to optimize clinical outcomes in medical cannabis treatment. This platform leverages big data analysis and algorithms based on expert best practices, integrating real-world patient outcomes with human and machine intelligence. Utilizing machine learning, IoT, mobile applications, and predictive analytics, ASAYA provides practical guidance for medical cannabis use, benefiting healthcare providers, patients, growers, and researchers within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Medical Cannabis.
Strategic signal
In May 2019, Ori Yehudai, known for the $7.1 billion sale of Frutarom, joined. This move signaled significant external validation and brought substantial industry experience and capital to the company, indicating a strategic push for growth and market penetration in the medical cannabis sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Sade Group's primary focus?
- Sade Group focuses on developing cannabis-based pharmaceutical products and a platform for optimizing medical cannabis treatment outcomes.
- What is the ASAYA platform?
- ASAYA is a platform developed by Sade Group that uses big data analysis and algorithms to manage medical cannabis treatment, integrating real-world practice and patient-reported outcomes with human and machine intelligence.
- When was Sade Group founded?
- Sade Group was founded in December 2015.
- What significant leadership change occurred in May 2019?
- In May 2019, Ori Yehudai, following the $7.1 billion sale of Frutarom, joined.
- Did Ori Yehudai remain with Sade Group?
- Ori Yehudai left Sade Group in July 2019, two months after joining as active chairman and investor.